|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
A single infliximab dose before pegylated-interferon α2b and ribavirin therapy did not result in greater viral decline during the first 12 weeks of HCV therapy or improved SVR.
|
24212915 |
2014 |
|
Hepatitis C
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The in cellulo anti-HCV activity of hLF was additive to both Ribavirin and Interferon-α-2b.
|
25193851 |
2014 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conducted a short-course (4 weeks) of pegylated interferon alpha-2a (Peg-IFN-α2a) plus ribavirin (RBV) to prevent of HCV recurrence.
|
24849835 |
2014 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Skewed Treg : Th17 ratios existed in chronic hepatitis C. HCV RNA load is closely associated with Treg : Th17 ratios during pegylated interferon-α2a and ribavirin treatment in HCV-infected patients.
|
24903732 |
2014 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The efficacy and tolerability of Peg-IFNα-2a and RBV, the cumulative dose effect, time to achieve planned cumulative dose and role of HCV phenotype on treatment response were determined in patients with decompensated HCV-induced cirrhosis.
|
25453135 |
2014 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the safety and efficacy of simeprevir with peg-interferon α-2a and ribavirin (PR) in a randomized, double-blind, placebo-controlled, phase 3 trial of patients with HCV genotype 1 infection who relapsed after previous interferon-based therapy.
|
24602923 |
2014 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
|
24709256 |
2014 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
We compared the measurement of HCV RNA by two Real-time PCR assays during the first 12weeks phase of telaprevir in combination with pegylated interferon α2b and ribavirin treatment for chronic hepatitis C patients.
|
23684903 |
2013 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.
|
24278242 |
2013 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients randomized to mericitabine with HCV RNA <15 IU/mL from week 4 to 22 (extended rapid virologic response; eRVR) stopped all treatment at week 24; all other patients continued Peg-IFNα-2a/RBV to complete 48 weeks of treatment.
|
23359491 |
2013 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
|
24297189 |
2013 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
SPRINT-1 was a randomized study of treatment-naive patients with genotype (G) 1 hepatitis C infection (n=595) that evaluated the safety and efficacy of boceprevir (BOC) when added to pegylated interferon-α2b plus ribavirin (PR).
|
23406826 |
2013 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
We included published Phase II and III randomized controlled trials evaluating head-to-head comparisons between boceprevir, telaprevir, peg-interferon alpha-2a with ribavirin and peg-interferon alpha-2b with ribavirin in hepatitis C genotype 1 patients.
|
23159839 |
2013 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conducted a randomized, controlled trial to test the efficacy and safety of pretransplant pegylated interferon alpha-2b plus ribavirin (Peg-IFN-α2b/RBV) for prevention of post-transplant HCV recurrence.
|
22821361 |
2013 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to analyze the predictive value of CXCL9, CXCL10, and CXCL11 concentrations before and after 4 and 12 weeks of treatment with pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C infected with the hepatitis C virus genotype 1.
|
22799464 |
2012 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.
|
21865660 |
2012 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
|
22246829 |
2012 |
|
Hepatitis C
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recently, elevated bile salt levels were shown to be significantly associated with rates and risk of cirrhosis in patients with chronic hepatitis C virus (HCV) infection treated with pegylated interferon-α2 and ribavirin, suggesting a potential role for bile salt levels in HCV treatment outcomes and in the fibrogenic evolution of HCV-related liver disease.
|
22681771 |
2012 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to document in real life the characteristics and management of hepatitis C patients treated with pegylated interferon-α2a and ribavirin, and the efficacy of treatment (sustained virological response [SVR]).
|
22267474 |
2012 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Concurrent autoimmune hepatitis and grave's disease in hepatitis C during pegylated interferon α-2a and ribavirin therapy.
|
21912063 |
2012 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Plasma samples from HCV genotype 2 or 3-infected patients participating in the NORDynamIC trial (n=382) comparing 12 and 24 weeks of combination treatment with pegylated interferon-α2a and a fixed dose of 800 mg ribavirin daily were analyzed for coreAg.
|
22113307 |
2012 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to compare the efficacy and tolerability of pegylated interferon (PEG-IFN) plus ribavirin (RIB) and PEG-IFN monotherapy after unsuccessful initial therapy with interferon-α2b (IFN) plus RIB after recurrent post-transplantation hepatitis C.
|
20438578 |
2011 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial.
|
20367790 |
2011 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Post-transplant treatment with pegylated interferon alpha-2a and ribavirin achieved SVR in 56% of liver transplant recipients with chronic HCV genotype 4 infection.
|
21221800 |
2011 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
|
20490669 |
2011 |